how come no reports to sound “all clear”? or pending a second swab in 2 weeks?
-
IP addresses are NOT logged in this forum so there's no point asking. Please note that this forum is full of homophobes, racists, lunatics, schizophrenics & absolute nut jobs with a smattering of geniuses, Chinese chauvinists, Moderate Muslims and last but not least a couple of "know-it-alls" constantly sprouting their dubious wisdom. If you believe that content generated by unsavory characters might cause you offense PLEASE LEAVE NOW! Sammyboy Admin and Staff are not responsible for your hurt feelings should you choose to read any of the content here. The OTHER forum is HERE so please stop asking.
[COVID-19 Virus] The Sinkies are fucked Thread.
- Thread starter zhihau
- Start date
how come no reports to sound “all clear”? or pending a second swab in 2 weeks?
your prediction came true - Sembawang Camp tio liao!
no news is good news.
Now childcare and students enrichment centres planning online classes to standby.
tiagong from my kakis that now hamapalang any household member not well, students can stay at home liao.
This virus very tok kong right?
If you don't acknowledge its true origins, you will never return to normalcy. You can mess around with vaccines, ambassadors, tokens, apps, CBs, masks etc. There will be no end in sight.
https://twitter.com/LawrenceSellin
If you don't acknowledge its true origins, you will never return to normalcy. You can mess around with vaccines, ambassadors, tokens, apps, CBs, masks etc. There will be no end in sight.
https://twitter.com/LawrenceSellin
MOH hotline at 1800-333-9999.
7 NEW CASES OF LOCALLY TRANSMITTED COVID-19 INFECTION
8TH MAY 2021
As of 8 May 2021, 12pm, the Ministry of Health (MOH) has preliminarily confirmed 7 new cases of locally transmitted COVID-19 infection, of whom 2 are linked to previous cases and had already been placed on quarantine. Based on our investigations so far, the cases are in the community, and there are no new cases in the dormitories.
2. In addition, there are 13 imported cases, who had already been placed on Stay-Home Notice or isolated upon arrival in Singapore. Amongst them, 9 are Singaporeans or Singapore Permanent Residents.
3. In total, there are 20 new cases of COVID-19 infection in Singapore today.
4. We are still working through the details of the cases, and further updates will be shared via the MOH press release that will be issued tonight.
MINISTRY OF HEALTH
8 MAY 2021
7 NEW CASES OF LOCALLY TRANSMITTED COVID-19 INFECTION
8TH MAY 2021
As of 8 May 2021, 12pm, the Ministry of Health (MOH) has preliminarily confirmed 7 new cases of locally transmitted COVID-19 infection, of whom 2 are linked to previous cases and had already been placed on quarantine. Based on our investigations so far, the cases are in the community, and there are no new cases in the dormitories.
2. In addition, there are 13 imported cases, who had already been placed on Stay-Home Notice or isolated upon arrival in Singapore. Amongst them, 9 are Singaporeans or Singapore Permanent Residents.
3. In total, there are 20 new cases of COVID-19 infection in Singapore today.
4. We are still working through the details of the cases, and further updates will be shared via the MOH press release that will be issued tonight.
MINISTRY OF HEALTH
8 MAY 2021
Yes, this I agree. Life has to go back to normal, there's no point having circuit breaker or lockdown whatever u call it. This virus will go on n on n it'll keep mutating to many variants till it'll eventually taper off slowly...
Last edited:
and eventually became a seasonable flu. Once a year, the world will have to lock down as preventative measure. It will become a trend every city and country. Singapore business model has to change and those who relied less on foreigners tend to sustain well.
Vaccinations will not stop the virus either. Reports of fully vaccinated people getting infected.
Vaccinations are like smartphones. You always want the latest version.Vaccinations will not stop the virus either. Reports of fully vaccinated people getting infected.
A massage establishment in Holland Drive has been taken to task for failing to inform the police that one of its staff had tested positive for Covid-19.
The staff member was reported as positive for the coronavirus on May 1, but the operator did not inform the Police Licensing and Regulatory Department (PLRD) when it found out, said the police yesterday. The police have since issued the outlet with a notice of composition.
Although the police did not identify the spa, the Health Ministry on May 2 had revealed that a 22-year-old female Malaysian, who works as a spa therapist at Spa 9 at 41 Holland Drive, had tested positive for Covid-19.
https://tinyurI.com/pwdz54h6
The staff member was reported as positive for the coronavirus on May 1, but the operator did not inform the Police Licensing and Regulatory Department (PLRD) when it found out, said the police yesterday. The police have since issued the outlet with a notice of composition.
Although the police did not identify the spa, the Health Ministry on May 2 had revealed that a 22-year-old female Malaysian, who works as a spa therapist at Spa 9 at 41 Holland Drive, had tested positive for Covid-19.
https://tinyurI.com/pwdz54h6
"girls working that day were hannah, jocelyn and cynthia." -cheongster
Although the police did not identify the spa, the Health Ministry on May 2 had revealed that a 22-year-old female Malaysian, who works as a spa therapist at Spa 9 at 41 Holland Drive, had tested positive for Covid-19.
https://tinyurI.com/pwdz54h6
Although the police did not identify the spa, the Health Ministry on May 2 had revealed that a 22-year-old female Malaysian, who works as a spa therapist at Spa 9 at 41 Holland Drive, had tested positive for Covid-19.
https://tinyurI.com/pwdz54h6
Wrong. Again. Call it 0 for 177 tries.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01018-7/fulltext
COVID-19 vaccine impact in Israel and a way out of the pandemic
Published:May 05, 2021
In December, 2020, Israel initiated a national campaign to vaccinate its population with Pfizer–BioNTech's mRNA COVID-19 vaccine BNT162b2 (tozinameran). Israel's Ministry of Health recommended a two-dose schedule with a 21-day interval between doses. Israel delivered more than 10 million doses within 4 months; by April 19, 2021, 54% of the entire population of 9·1 million people, and 88% of people aged 50 years or older, had received two doses.
1
Factors contributing to Israel's rapid roll-out include its small geographical and population sizes; advanced information technology that allowed prioritisation, allocation, and documentation of vaccines for eligible individuals; effective cooperation between government and community-based health funds, which were charged with providing vaccines to those they insured; and experience in rapid large-scale emergency responses.
2
Vaccines were rolled out around the time of Israel's third and largest wave of SARS-CoV-2 infections, with a peak 7-day moving average of 8328 new infections per day, which resulted in a 2-month national lockdown. Thus, Israel's setting provided a robust platform on which to examine vaccine effectiveness and the impact of high vaccine coverage in real-life conditions at a national level. From March, 2021, onwards, Israel reported a rapid decline in COVID-19 cases across all age groups, despite the easing of lockdown restrictions and reopening of education and commerce. By April 19, 2021, the 7-day moving average of new cases dropped to 149 per day, indicating effective control of the pandemic within the country's borders.
1
,
3
The marked reduction in new cases prompted the Israeli Government to ease nationwide restrictions, including the discontinuation of face covering use in open spaces.
• View related content for this article
In The Lancet, Eric Haas and colleagues report on a nationwide observational study of the impact and vaccine effectiveness of BNT162b2 in Israel.
3
Israel's Ministry of Health used aggregated data from the national SARS-CoV-2 surveillance and vaccination programme dataset to compare infection and disease incidence between vaccinated and unvaccinated people. Overall, of 232 268 SARS-CoV-2 infections during the study period (Jan 24 to April 3, 2021), 154 648 (66·6%) occurred in people aged 16 years or older and were included in the analyses (of which 20·4% were in the Arab sector, 15·7% in the ultra-Orthodox sector, and 63·9% in the general Jewish [non-ultra-Orthodox] sector). Adjusted estimates of vaccine effectiveness at 7 days or longer after the second dose were 95·3% (95% CI 94·9–95·7) against SARS-CoV-2 infection, 91·5% (90·7–92·2) against asymptomatic SARS-CoV-2 infection, 97·0% (96·7–97·2) against symptomatic SARS-CoV-2 infection, 97·2% (96·8–97·5) against COVID-19-related hospitalisation, 97·5% (97·1–97·8) against severe or critical COVID-19-related hospitalisation, and 96·7% (96·0–97·3) against COVID-19-related death. Vaccine effectiveness against symptomatic SARS-CoV-2 infection, COVID-19-related hospitalisation, and COVID-19-related death exceeded 96% across all age groups, including older adults (aged ≥75 years and ≥85 years). These results closely mirror the efficacy estimates of the BNT162b2 vaccine reported in the phase 3 trial.
4
The strengths of the study include its nationwide design, mandatory routine reporting of new infections and of vaccination status to the national dataset, large sample size, exclusive use of BNT162b2, and occurrence of a highly efficient vaccine roll-out during peak transmission of SARS-CoV-2, which resulted in high vaccination coverage of most of the adult population. However, several limitations should be considered when interpreting the results. First, social desirability bias affecting symptom questionnaire respondents and presymptomatic infections at the time of questioning could have contributed to an overestimation of vaccine effectiveness against asymptomatic infection. Additionally, patients with COVID-19 who reported symptoms were defined as asymptomatic if they did not report fever or respiratory symptoms. This unorthodox case definition might have resulted in a substantial overestimation of vaccine effectiveness against asymptomatic SARS-CoV-2 infection.
5
Second, during early 2021, the B.1.1.7 variant of SARS-CoV-2 was estimated to account for 95% of cases in Israel, and the results thus indicate that the vaccine was effective against this variant of concern. However, the study did not report on effectiveness against other variants of concern, such as B.1.351 and P.1. Concerns regarding breakthrough infections were recently raised as a case-cohort study from Israel reported a disproportionally high infection rate with the B.1.351 variant in fully vaccinated compared with unvaccinated individuals.
6
Nevertheless, the incidence of B.1.351 infection in Israel to date remains low. Rapid mass vaccination coupled with non-pharmaceutical interventions
7
might have successfully controlled its spread.
Haas and colleagues' findings from Israel suggest that high vaccine coverage rates could offer a way out of the pandemic.
5
,
8
Regrettably, rapid population level coverage cannot be easily replicated in many other countries. The global use of the BNT162b2 vaccine is limited by supply issues, high costs, and ultra-cold chain storage requirements. Global COVID-19 vaccine roll-out has been sluggish, and vaccine distribution is inequitable despite the achievements of COVAX, mainly due to the lack of adequate manufacturing scalability.
9
,
10
Rapid expansion of deployment of other effective vaccines with more achievable cold chain storage requirements remains an urgent global priority.
9
Facing such challenges, alternative approaches must be considered to allow rapid protection of at-risk populations against severe COVID-19. One such approach is deferring the second dose to accelerate and maximise coverage of the first dose in the population. Indeed, the situation in Scotland looks promising: the first dose of BNT162b2 was associated with a vaccine effectiveness of 91% (85–94) for COVID-19-related hospitalisation at 28–34 days post-vaccination.
11
Israel's robust dataset could allow further assessment and corroboration of first-dose short-term effectiveness and lead other countries to considering deferring the second vaccine dose.
3
Post-introduction vaccine effectiveness studies such as those from Israel
3
and the UK
5
,
11
will gain increasing importance in augmenting the current evidence, which has so far been based only on data from phase 3 efficacy trials. WHO has published a best practice guidance document on how to conduct vaccine effectiveness assessments using observational study designs.
12
Israel's experience provides impetus for countries to proactively pursue high vaccine coverage to protect the population;
8
however, rollout would need to follow the WHO prioritisation roadmap to maximise the public health impact, in light of vaccine supply constraints. More post-introduction vaccine effectiveness studies will be required. Timely reporting of vaccine effectiveness against variants of concern, the duration of protection across age groups and geographical settings, and the effectiveness of alternative dosing regimens is crucial to provide data-driven immunisation policies.
12
Copyright © 2021 Amir Levy/Stringer/Getty Images
EL reports personal fees from Sanofi Pasteur for participation in a global advisory board of influenza vaccination, outside the area of work commented on here. AW-S serves as a consultant to WHO's Immunization and Vaccination Department. The authors alone are responsible for the views expressed in this Comment, and they do not necessarily represent the decisions or policies of WHO.
References
- 1.
- Israel Ministry of Health
- COVID-19 daily situation report.
https://datadashboard.health.gov.il/COVID-19/general
Date accessed: April 20, 2021
(in Hebrew).
View in Article - 2.
- Rosen B
- Waitzberg R
- Israeli A
- Israel's rapid rollout of vaccinations for COVID-19.
Isr J Health Policy Res. 2021; 10: 6
Similar threads
